In the study, supplementation alone did not have a significant impact on cardiovascular outcomes in patients who've recovered from mycocardial infarction. However, subjects taking omega-3s that had a 5% increase in omega-3 index did see better health outcomes than those who did not.
A recently published study1 found that omega-3 supplementation six months after acute myocardial infarction (AMI) may have a beneficial long-term impact on cardiovascular health. In the study, called the OMEGA-REMODEL randomized clinical trial, 358 patients who had experienced an AMI received either 4 grams daily of omega-3 fatty acids or placebo for six months. These subjects were followed for a median of six years. The primary outcome of the study was a composite of major adverse cardiovascular events (MACE) that encompass all-cause death, heart failure hospitalization, recurrent acute coronary syndrome, and late coronary artery bypass graft.
Results showed that the group of patients that received omega-3s did not see a decrease in MACE compared to placebo. However, researchers did find that subjects (n=43) that had an increase in the red blood cell omega-3 index greater than or equal to 5% after six months of treatment did have lower annualized MACE rates compare to those without an increase in omega-3 index. These results therefore indicate that a treatment strategy that aims to increase omega-3 index by 5% may lead to favorable outcomes after AMI.
“It is one thing to take an omega-3 supplement, but it’s quite another to taken enough to achieve a healthy target level in your own blood,” explained William S. Harris, PhD, one of the study’s authors, and president of the Fatty Acid Research Institute (FARI); founder of OmegaQuant Analytics, LLC; and Professor, Department of Internal Medicine, Sanford School of Medicine, University of South Dakota.
“Maybe they were more faithful in taking their capsules; maybe they took them with food instead of on an empty stomach; maybe they have a genetic predisposition to better absorption/incorporation of EPA and DHA into their cells,” Harris added. “It’s not clear why some people did see an increase in their omega-3 index and others did not, but it appears that that’s what was most important in reducing their long-term risk for MACE.”
Reference
New study shows that vitamin K2 as MK-7 may have neuroprotective qualities
May 17th 2024Researchers examined the effects of MK-7 and menaquinone-4 (MK-4) on neuroblastoma cells to understand how different forms of vitamin K2 impact the expression of genes involved in neurodegeneration and neuroinflammation.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.